Dr. Charles E. Fisher Jr. is a Lubbock, Texas based male Ophthalmologist who is specialized in Ophthalmology. Active license number of Dr. Charles E. Fisher Jr. is E6348 for Ophthalmology in Texas. Dr. Charles E. Fisher Jr. is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Dr. Charles E. Fisher Jr. speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Credentials:
M.D.
Gender:
Male
Practice Address:
4613 13th St, Lubbock, Texas, 79416-4823
Phone:
806-795-3680
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1336231265
NPI Enumeration Date:
28 Sep, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Charles E. Fisher Jr. are as mentioned below.
License Number
Specialization
State
Status
E6348
Ophthalmology
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
4613 13th St, Lubbock, Texas
Zip:
79416-4823
Phone Number:
806-795-3680
Fax Number:
--
Patients can reach Dr. Charles E. Fisher Jr. at 4613 13th St, Lubbock, Texas or can call to book an appointment on 806-795-3680. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.